Gene therapy for aging: revision 2 to 3

Revision 2

Revision 3

categories: ["longevity", "genetics"]

tags: ["gene therapy", "aav", "telomerase", "klotho", "follistatin", "aging", "self-experimentation"]

summary: "The use of delivered genes to modify aging biology systemically, demonstrated in mice with telomerase and other constructs and untested in any controlled human trial."

summary: "The use of delivered genes to modify aging biology systemically, demonstrated in mice with telomerase and other constructs and untested in any controlled human trial."

updated: "2026-10-28"

updated: "2026-10-29"

humanEvidence: "No controlled trial has tested any of these constructs against aging in people; the human record is self-administration and single-arm offshore studies without published results, plus early-phase trials in muscle and eye disease."

humanEvidence: "No controlled trial has tested any of these constructs against aging in people; the human record is self-administration and single-arm offshore studies without published results, plus early-phase trials in muscle and eye disease."

access: "Not approved for any aging indication; offshore ventures have charged for unapproved telomerase and follistatin constructs at reported prices from about $25,000 to $1 million per dose."

access: "Not approved for any aging indication; offshore ventures have charged for unapproved telomerase and follistatin constructs at reported prices from about $25,000 to $1 million per dose."

reversibility: "context"

**Gene therapy for aging** is the delivery of genetic material to a large fraction of an adult's

cells with the aim of changing the trajectory of aging itself rather than treating a single inherited

disease. It differs from ordinary [[somatic-gene-therapy]] in ambition rather than in method: the

disease. The methods are those of ordinary [[somatic-gene-therapy]]; the ambition is larger. The

same viral vectors and nucleic-acid payloads, aimed at systemic targets like telomere maintenance,

same viral vectors and nucleic-acid payloads are aimed at systemic targets such as telomere

muscle mass, or epigenetic state, and given to people who are not sick by any current definition. As

maintenance, muscle mass, or epigenetic state, and given to people who are not sick by any current

of 2026 the animal results are real and the human record consists almost entirely of unregulated

definition. As of 2026 the animal results are real, and the human record consists almost entirely of

self-experimentation.

unregulated self-experimentation.

## The animal evidence

The founding result is telomerase. A 2012 study delivered the mouse TERT gene in an adeno-associated

The founding result came from telomerase. A 2012 study delivered the mouse TERT gene in an

viral vector to adult mice and reported extended median lifespan, with a larger effect in animals

adeno-associated viral vector to adult mice and reported extended median lifespan, with a larger

treated at one year of age than at two, and without an observed increase in cancer

effect in animals treated at one year of age than at two, and without an observed increase in cancer

incidence.[^bernardes2012] That last clause is the striking part, because telomerase reactivation is

incidence.[^bernardes2012] The lack of an observed cancer increase is the surprising part, because

a near-universal feature of tumours, and the finding has not been reproduced widely enough to settle

telomerase reactivation is a near-universal feature of tumours, and the finding has not been

the safety question. Its interpretation depends on the broader argument covered under

reproduced widely enough to settle the safety question. How much it means depends on the broader

[[telomeres-and-telomerase]], where telomere attrition is a weaker driver of human aging than of

argument covered under [[telomeres-and-telomerase]]: in several respects telomere attrition is a weaker driver of

mouse aging in several respects.

human aging than of mouse aging.

Two other targets recur. [[klotho|Klotho]], a protein whose loss in mice produces a syndrome resembling

accelerated aging and whose overexpression extends mouse lifespan,[^kurosu2005] has been pursued both

after peripheral klotho administration, in small numbers and without long-term follow-up. Follistatin

blocks myostatin signalling and reliably increases muscle mass when delivered by AAV to mice and

monkeys; early-phase trials in muscular dystrophy have reported modest and inconsistent functional

change,[^mendell2015] and the relationship between added muscle mass and added strength is not

change,[^mendell2015] and added muscle mass does not translate simply into added strength, the

straightforward — the issue treated in [[myostatin-inhibition]].

issue treated in [[myostatin-inhibition]].

The newest line delivers reprogramming factors rather than a single protein. Vectors carrying OSK, the

The newest line of work delivers reprogramming factors instead of a single protein. Vectors carrying

three-factor subset of the [[yamanaka-factors]] that omits the oncogene MYC, have been reported to

OSK, the three-factor subset of the [[yamanaka-factors]] that omits the oncogene MYC, have been

extend remaining lifespan in mice treated in old age: one study gave an inducible AAV-OSK system to

reported to extend remaining lifespan in mice treated in old age: one study gave an inducible

male mice aged 124 weeks and reported a 109% increase in median remaining lifespan, a result that has

AAV-OSK system to male mice aged 124 weeks and reported a 109% increase in median remaining

not been independently replicated.[^macip2024] In 2026 an OSK construct entered a registered human

lifespan, a result that has not been independently replicated.[^macip2024] In 2026 an OSK construct

trial aimed at a disease rather than at aging: Life Biosciences' ER-100, an AAV vector carrying

entered a registered human trial aimed at a disease rather than at aging: Life Biosciences' ER-100,

doxycycline-controlled OSK injected into one eye, began an open-label phase 1 safety study in

an AAV vector carrying doxycycline-controlled OSK injected into one eye, began an open-label phase 1

glaucoma and ischaemic optic neuropathy.[^registry2026] This work sits at the intersection of gene

safety study in glaucoma and ischaemic optic neuropathy.[^registry2026] This work sits at the

therapy and [[epigenetic-reprogramming]]; the dosing and duration questions are those of

intersection of gene therapy and [[epigenetic-reprogramming]]; the dosing and duration questions are

[[partial-reprogramming]].

those of [[partial-reprogramming]].

> [!caution] Mice are not the hard case

> A mouse lives under thirty months, weighs thirty grams, and can receive a vector dose per kilogram

## Why aging is a difficult target

Gene therapy works best where a single defective gene in a reachable tissue causes a defined disease.

Aging has none of those properties.

Aging meets none of those conditions.

*No single target.* The processes catalogued as [[hallmarks-of-aging]] are numerous and partly

independent. A construct that addresses telomere length leaves the others untouched,

independent. A construct that addresses telomere length leaves the others untouched, so proposals

which is why proposals in this space tend toward multi-gene combinations, each adding immunological

in this space tend toward multi-gene combinations, and each added gene brings immunological and

and manufacturing complexity.

manufacturing complexity.

*Delivery.* [[aav-vectors|AAV]] reaches the liver efficiently and most other tissues poorly, carries

a payload limit of about five kilobases, and provokes an immune response that prevents redosing with

*Permanence.* An AAV genome persists episomally in non-dividing cells for years and cannot be

withdrawn. For a transgene that promotes growth, blocks a tumour suppressor, or reactivates

telomerase, the absence of an off switch is a serious safety problem. Regulatable systems and

telomerase, the lack of an off switch is a serious safety problem. Regulatable systems and transient

transient mRNA delivery are the responses, at the cost of requiring repeated administration through a

mRNA delivery answer it, but they require repeated administration, and immunity tends to close that

route that immunity tends to close.

route.

*Risk-benefit.* High-dose systemic AAV has caused severe hepatotoxicity and deaths in trials for

serious childhood diseases. That risk is defensible when the alternative is a fatal disorder. Applied

serious childhood diseases. That risk is defensible when the alternative is a fatal disorder. It is

to a healthy sixty-year-old seeking a probabilistic benefit decades hence, the same risk is not, and

not defensible for a healthy sixty-year-old seeking a probabilistic benefit decades later. No

no regulator has an approval pathway for the indication — the same structural obstacle described under

regulator has an approval pathway for the indication either, the same structural obstacle described

[[geroscience-hypothesis]] and in [[metformin|the TAME proposal]].

under [[geroscience-hypothesis]] and in [[metformin|the TAME proposal]].

## Unregulated human use

Because no controlled trial for aging exists, the human record has been written largely outside conventional oversight.

Because no controlled trial for aging exists, most human use has happened outside conventional oversight.

In September 2015 the chief executive of the company BioViva, Elizabeth Parrish, received two gene

therapies outside the United States, reportedly in Colombia: follistatin, a myostatin inhibitor,

injected into muscle, and an intravenous viral vector carrying telomerase.[^regalado2015] BioViva

later announced, by press release, lengthening of her leukocyte telomeres measured by a commercial

assay. The result was not published in a journal, the assay is noisy, and one person is not a study.

assay. The result was not published in a journal, the assay is noisy, and a single person cannot

constitute a study.

In 2019 Libella Gene Therapeutics offered an AAV telomerase gene therapy at a clinic in Zipaquirá,

Colombia, at $1 million per dose,[^swain2019] a pay-to-participate structure that inverts the ethics

Colombia, at $1 million per dose.[^swain2019] The pay-to-participate structure inverts the ethics of

of clinical research by charging subjects for an unproven intervention. Its registry entries, each

clinical research by charging subjects for an unproven intervention. Its registry entries, each

for five participants, were last updated in 2019 and report no results.[^registry2026]

Minicircle, a Delaware-registered startup, doses volunteers in Próspera, a special economic zone on

Biotechnology, began an open-label phase 1/2a at a Roatán clinic in June 2026, combining an AAV9

follistatin vector with a VEGF plasmid for age-related muscle decline.[^registry2026]

These ventures share a pattern: jurisdiction shopping, absent control groups, surrogate endpoints

These ventures share a pattern: jurisdiction shopping, no control groups, surrogate endpoints chosen

chosen after the fact, and outcomes announced by press release. Registration on ClinicalTrials.gov,

after the fact, and outcomes announced by press release. The later ventures register on

which the later ventures have adopted, makes their designs visible without adding a control group.

ClinicalTrials.gov, which makes their designs visible but adds no control group. The ventures generate

They generate little usable knowledge and raise the regulatory temperature for the researchers doing

little usable knowledge and raise regulatory scrutiny for researchers doing the work properly.

the work properly.

## What a legitimate path would look like

Alzheimer's disease have entered early-phase trials, and one-time editing of PCSK9 to lower lifelong

cholesterol, using [[base-editing]] delivered in lipid nanoparticles and first shown to work durably

in non-human primates,[^musunuru2021] is the closest existing test of a durable genetic intervention

given for prevention rather than rescue. Neither is marketed as an aging therapy, and both would

given for prevention rather than rescue. Neither is marketed as an aging therapy, but both would set

establish precisely the precedents an aging therapy needs: acceptable risk in relatively healthy adults,

the precedents an aging therapy needs: acceptable risk in relatively healthy adults, a durable effect

durable effect from a single administration, and a regulatory framework for prevention.

from a single administration, and a regulatory framework for prevention.

Progress also depends on measurement. Without an accepted [[aging-biomarkers|biomarker of aging]] a

trial cannot read out in less than a decade, and neither an [[epigenetic-clock]] shift nor an

## Outlook

The near-term question is not whether aging can be treated genetically but whether any of the

The near-term question is whether any of the candidate constructs are worth the delivery risk, a

candidate constructs are worth the delivery risk. Telomerase carries an unquantified cancer liability;

narrower question than whether aging can be treated genetically at all. Telomerase carries an

follistatin adds muscle of uncertain functional value; reprogramming factors carry dedifferentiation

unquantified cancer liability; follistatin adds muscle of uncertain functional value; reprogramming

and teratoma risk that has been demonstrated in mice. Combination approaches multiply these problems

factors carry dedifferentiation and teratoma risk that has been demonstrated in mice. Combining them

rather than averaging them.

multiplies these problems instead of averaging them out.

If the field does mature, its main constraint may be economic rather than biological. One-time gene

therapies for rare disease already carry prices in the millions, and a therapy intended for everyone

above sixty would face a manufacturing and distribution problem of a different order — the concern

above sixty would face a manufacturing and distribution problem of a different order, the concern

argued out under [[access-and-inequality]].

## See also